8-K: Centene Reaffirms 2024 EPS Guidance Amidst Medicaid Claims Surge

Centene Corporation reaffirms its full-year 2024 adjusted diluted EPS guidance despite higher than expected Medicaid claims, while also noting strong Marketplace performance and a projected premium deficiency reserve.

Summary

• Centene Corporation is reaffirming its full-year 2024 adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
• The company also maintains its full-year consolidated health benefits ratio range of 87.3% to 87.9%.
• Higher than expected claims receipts were observed in April for both the first quarter of 2024 and April 2024 dates of service within the Medicaid segment.
• Early reads of May claims receipts indicate that medical costs in Medicaid continue to be higher than expected.
• Approximately 50% of the company's Medicaid rate changes are expected to occur between July 1 and October 1, 2024.
• The Marketplace segment is showing continued strong performance for 2024, including favorable 2023 risk adjustment outperformance in the second quarter of 2024.
• The company anticipates strong consolidated premium and service revenue and investment income performance in the second quarter and for the remainder of 2024.
• The Medicare segment is performing as expected in April 2024.
• The adjusted diluted EPS guidance now includes a fourth quarter 2024 projected premium deficiency reserve of approximately $125 million related to 2025 Medicare Advantage bids.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the reaffirmation of EPS guidance and strong Marketplace performance, but tempered by higher Medicaid claims and the premium deficiency reserve.

Positives

• Centene is reaffirming its full-year 2024 adjusted diluted EPS guidance.
• The Marketplace segment is performing strongly.
• The company expects strong consolidated premium and service revenue and investment income performance for the second quarter and the remainder of 2024.
• The Medicare segment is on track with expectations in April 2024.

Negatives

• Medicaid claims receipts were higher than expected in April and early May, indicating higher medical costs.
• A $125 million premium deficiency reserve is projected for the fourth quarter of 2024 related to 2025 Medicare Advantage bids.

Risks

• Higher than expected medical costs in the Medicaid segment could impact profitability.
• The timing of Medicaid rate changes, with 50% expected between July 1 and October 1, 2024, could introduce uncertainty.
• The $125 million premium deficiency reserve for Medicare Advantage bids could affect earnings.
• The company's ability to accurately predict and manage health benefits and other operating expenses and reserves is a risk.
• Changes in healthcare practices, new technologies, and advances in medicine could impact the business.
• The company faces risks related to competition, regulatory changes, and economic conditions.

Future Outlook

Centene expects to reaffirm its 2024 full-year adjusted diluted EPS guidance and health benefits ratio range, while also anticipating strong performance in the Marketplace segment and continued revenue growth. The company also projects a premium deficiency reserve in Q4 related to 2025 Medicare Advantage bids.

Management Comments

• The Company expects to reaffirm the 2024 full year adjusted diluted earnings per share (EPS) guidance of greater than $6.80.
• The Company expects to reaffirm the full year consolidated health benefits ratio range of 87.3% to 87.9%.

Industry Context

This announcement comes as healthcare providers and insurers are navigating changes in government programs, including Medicaid redeterminations and risk adjustment mechanisms. The higher than expected Medicaid claims highlight the ongoing challenges in managing healthcare costs, while the strong Marketplace performance indicates a positive trend in that segment. The premium deficiency reserve for Medicare Advantage bids reflects the competitive landscape and the need for accurate pricing.

Comparison to Industry Standards

• Centene's reaffirmation of its EPS guidance is a positive sign, but the higher Medicaid claims are a concern that other managed care companies may also be facing.
• Competitors like UnitedHealth Group and Humana also operate in the Medicaid and Medicare markets, and their performance in these segments will be a key comparison point.
• The health benefits ratio is a key metric for managed care companies, and Centene's guidance of 87.3% to 87.9% will be compared to industry averages and competitor performance.
• The $125 million premium deficiency reserve is a significant amount and will be compared to similar reserves taken by other companies in the Medicare Advantage space.

Stakeholder Impact

• Shareholders may react positively to the reaffirmed EPS guidance but negatively to the higher Medicaid claims and premium deficiency reserve.
• Employees may be affected by any changes in operational strategies to address the higher medical costs.
• Customers may experience changes in service or premiums due to the company's financial performance.
• Suppliers and providers may be impacted by any changes in payment rates or contract terms.

Next Steps

• Centene will present at the Bernstein 40th Annual Strategic Decisions Conference on May 31, 2024.
• The company will provide additional detail on its second quarter 2024 earnings call in late July.

Key Dates

Keywords

Medicaid, Medicare, EPS, Health Benefits Ratio, Marketplace, Claims, Premium Deficiency Reserve, Healthcare, Insurance